Randomised Controlled Trial of 6-Mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgic

S克隆病是一种影响肠道的慢性致残性疾病。虽然内科治疗是有效的，但在确诊后的头5年里，大约50%的患者需要手术切除受影响的肠段。手术后复发的患者占大多数。6-巯基嘌呤是一种有效的治疗克罗恩-S病的方法，但其在预防术后复发方面的作用尚不明确。之前的研究规模很小，要么是追溯性的，要么是设计上的缺陷。在这项多中心研究中，我们希望评估药物6-巯基嘌呤预防克隆氏S病术后复发的价值。我们将使用症状的复发作为主要结果衡量标准，相关区域的内窥镜检查和是否需要进一步手术作为次要结果衡量标准。如果这项试验显示了该药物的效果，我们预计克罗恩S病患者手术后将获得广泛的吸收并改善生活质量。

Crohn s disease is a chronic disabling condition affecting the bowel. Although medical treatment is effective approximately 50% of patient will need an operation to remove an affected segment of bowel over the first 5 years after diagnosis. Recurrence following surgery occurs in the majority of patients. 6-Mercaptopurine is an effective treatment for the reduction of symptoms and maintenance of well being in Crohn s disease but its use to prevent post operative recurrence is poorly defined. Previous studies have been small, retrospective or flawed in design. In this multicentre study we wish to assess the value of the drug 6-mercaptopurine to prevent recurrence of Crohn s disease following surgery. We will use the recurrence of symptoms as the primary outcome measure, with endoscopic examination of the relevant area and the need for further sugery as secondary outcome measures. If this trial were to show an effect of the drug we would anticipate a wide uptake and improved quality of life for patients with Crohn s disease following surgery.